References
- Simon R . The use of genomics in clinical trial design. Clin. Cancer Res.14(19) , 5984–5993 (2008).
- Braun MS , RichmanSD, QuirkeP et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26(16) , 2690–2698 (2008).
- Gamazon ER , HuangRS, CoxNJ, DolanME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl Acad. Sci. USA107(20) , 9287–9292 (2010).
- Sarkar FH , LiY, WangZ, KongD, AliS. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Update13(3) , 57–66 (2010).
- Schwarz DF , SzymczakS, ZieglerA, KonigIR. Evaluation of single-nucleotide polymorphism imputation using random forests. BMC Proc.3(Suppl. 7) , S65 (2009).
- Van‘t Veer LJ , BernardsR. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature452(7187) , 564–570 (2008).
- Dressman HK , HansC, BildA et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin. Cancer Res. 12(3 Pt 1) , 819–826 (2006).
- Lin Y , LinS, WatsonM et al. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 123(3) , 691–699 (2010).
- Parissenti AM , HembruffSL, VilleneuveDJ, VeitchZ, GuoB, EngJ. Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells. Anticancer Drugs18(5) , 499–523 (2007).
- Kim BK , LeeJW, ParkPJ et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 11(2) , R22 (2009).
- Statnikov A , WangL, AliferisCF. A comprehensive comparison of random forests and support vector machines for microarray-based cancer classification. BMC Bioinformatics9 , 319 (2008).
- Del Rio M , MolinaF, Bascoul-MolleviC et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 25(7) , 773–780 (2007).
- Dressman HK , BerchuckA, ChanG et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25(5) , 517–525 (2007).
- Hess KR , AndersonK, SymmansWF et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24(26) , 4236–4244 (2006).
- Harris LN , YouF, SchnittSJ et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13(4) , 1198–1207 (2007).
- Hayes DN , MontiS, ParmigianiG et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol. 24(31) , 5079–5090 (2006).
- Tebbit CL , ZhaiJ, UntchBR et al. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res. Treat. 118(3) , 635–643 (2009).
- Bild AH , YaoG, ChangJT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439(7074) , 353–357 (2006).
- Potti A , DressmanHK, BildA et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12(11) , 1294–1300 (2006).
- Williams PD , CheonS, HavaleshkoDM et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 69(21) , 8302–8309 (2009).
- Ioannidis JP , AllisonDB, BallCA et al. Repeatability of published microarray gene expression analyses. Nat. Genet. 41(2) , 149–155 (2009).
- Baggerly KA , CoombesKR. What information should be required to support clinical ‘omics‘ publications? Clin. Chem. doi:10.1373/clinchem.2010.158618(2011) (Epub ahead of print).
- Borst P , WesselsL. Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle9(24) , 4836–4840 (2010).
- Lee JK , CoutantC, KimYC et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin. Cancer Res. 16(2) , 711–718 (2010).
- Bonnefoi H , PottiA, DelorenziM et al. Retraction – validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00–01 clinical trial. Lancet Oncol. 12(2) , 116 (2011).
- Saeys Y , InzaI, LarranagaP. A review of feature selection techniques in bioinformatics. Bioinformatics23(19) , 2507–2517 (2007).
- Talby L , ChambostH, RoubaudMC et al. The chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia could be determined by the combined expression of CD34, SPI-B and BCR genes. Leuk. Res. 30(6) , 665–676 (2006).
- Duong C , GreenawaltDM, KowalczykA et al. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann. Surg. Oncol. 14(12) , 3602–3609 (2007).
- Huang CC , GaddS, BreslowN et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children‘s Oncology Group. Clin. Cancer Res. 15(5) , 1770–1778 (2009).
- Tsuji S , MidorikawaY, TakahashiT et al. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br. J. Cancer doi:10.1038/bjc.2011.505 (2011) (Epub ahead of print).
- Pengyi Y , YangYH, ZhouBB, ZomayaAY, A review of ensemble methods in bioinformatics. Curr. Bioinformatics5(4) , 296–308 (2010).
- Diaz-Uriarte R , Alvarez De Andres S. Gene selection and classification of microarray data using random forest. BMC Bioinformatics7 , 3 (2006).
- Thuerigen O , SchneeweissA, ToedtG et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 24(12) , 1839–1845 (2006).
- Pers TH , AlbrechtsenA, HolstC, SorensenTI, GerdsTA. The validation and assessment of machine-learning: a game of prediction from high-dimensional data. PLoS ONE4(8) , e6287 (2009).
- Shi L , CampbellG, JonesWD et al. The MicroArray Quality Control (MAQC) II study of common practices for the development and validation of microarray-based predictive models. Nat. Biotechnol. 28(8) , 827–838 (2010).